| [1] |
Bevrah hahn, Maureena mcmahon, Alan Wilkinson, et al. American College of Rheumatology Guidelines for Screening, Treatment, and Management of Lupus Nephritis. Arthritis Care & Research, 2012,64(6):797-808.
|
| [2] |
Lerournel E. Acetabuium factures：classification and management. Clin rthop，1980, (151):81-106.
|
| [3] |
KDIGO Clinical Practice Guideline for Glomerulonephritis. Official journal of the international society of nephrology, 2012, 2(2)．
URL
|
| [4] |
Bertsias GK, Tektonidou M, Amoura Z，et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis, 2012, 71(11):1771-1782.
|
| [5] |
栗占国，唐福林. 凯利风湿病学. 8版. 北京：北京大学医学出版社，2011: 1350.
|
| [6] |
Shan HY, Rana S, Epstein FH，et al. Use of circulating antiangiogenic factors to differentiate other hypertensive disorders from preeclampsia in a pregnant woman on dialysis. Am J Kidney Dis, 2008,51(6):1029-1032.
|
| [7] |
Saavedra MA, Cruz-Reyes C, Vera-Lastra O, et al. Impact of previous lupus nephritis on maternal and fetal outcomes during pregnancy. Clin Rheumatol, 2012, 31(5):813-819.
|
| [8] |
Hviid A, Mølgaard-Nielsen D. Corticosteroid use during pregnancy and risk of orofacial clefts. CMAJ, 2011, 183(7):796-804.
|
| [9] |
Fraser FC, Fainstat TD. Production of congenital defects in the off-spring of pregnant mice treated with cortisone; progress report. Pediatrics, 1951, 8(4):527-533.
|
| [10] |
Fraser FC, Sajoo A. Teratogenic potential of corticosteroids in humans. Teratology, 1995, 51(1):45-46.
|
| [11] |
EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.6.1. Cancer risk after renal transplantation. Post-transplant lymphoproliferative disease (PTLD): prevention and treatment. Nephrol Dial Transplant, 2002, 17 Suppl 4:31-33, 35-36.
|
| [12] |
Cleary BJ, Kallen B. Early pregnancy azathioprine use and pregnancy outcomes. Birth Defects Res A Clin Mol Teratol，2009,85(7):647-654.
|
| [13] |
Ostensen M, Khamashta M, Lockshin M, et al. Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther，2006, 8(3):209.
|
| [14] |
Clowse ME, Magder L, Witter F, et al. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum, 2006,54(11):3640-3647.
|
| [15] |
Kyle PM. Drugs and the fetus. Curr Opin Obstet Gynecol，2006,18(2):93-99.
|
| [16] |
Davison JM, Nelson-Piercy C, Kehoe S, et al. Consensus views arising from the 54th Study Group: Renal disease in pregnancy. London: RCOG Press, 2008.
|
| [17] |
Royal College of Obstetricians and Gynaecologists. Reducing the Risk of Thrombosis and Embolism during Pregnancy and the Puerperium Green-top Guideline No.37. London: RCOG Accessed online 2009)．
URL
|
| [18] |
Duley L, Henderson-Smart DJ, Meher S, et al. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev, 2007, 18(2):CD004659.
|
| [19] |
Imbasciati E, Tincani A, Gregorini G, et al. Pregnancy in women with pre-existing lupus nephritis: predictors of fetal and maternal outcome. Nephrol Dial Transplant, 2009,24(2):519-525.
|